Critical Comparison: TScan Therapeutics (NASDAQ:TCRX) versus Tiziana Life Sciences (NASDAQ:TLSA)

TScan Therapeutics (NASDAQ:TCRX) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends.

Insider & Institutional Ownership

82.8% of TScan Therapeutics shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares TScan Therapeutics and Tiziana Life Sciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32 million	6.13	-$129.77 million	($0.96)	-1.01
Tiziana Life Sciences	N/A	N/A	-$18.43 million	N/A	N/A

Tiziana Life Sciences has lower revenue, but higher earnings than TScan Therapeutics.

Profitability

This table compares TScan Therapeutics and Tiziana Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%
Tiziana Life Sciences	N/A	N/A	N/A

Volatility and Risk

TScan Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for TScan Therapeutics and Tiziana Life Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1	2	3	0	2.33
Tiziana Life Sciences	1	0	0	0	1.00

TScan Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 519.32%. Given TScan Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe TScan Therapeutics is more favorable than Tiziana Life Sciences.

Summary

TScan Therapeutics beats Tiziana Life Sciences on 6 of the 11 factors compared between the two stocks.

About TScan Therapeutics

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.